
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.600 | 3.350 | 2.750 |
Shares | 99.400 | 99.400 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 28.701 | 31.071 |
Price to Book | - | 3.621 |
Price to Sales | 3.770 | 5.004 |
Price to Cash Flow | 15.843 | 19.830 |
Dividend Yield | 0.438 | 0.739 |
5 Years Earnings Growth | 24.985 | 17.904 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 81.940 | 95.929 |
Energy | 6.860 | 6.860 |
Consumer Defensive | 5.970 | 5.970 |
Technology | 5.230 | 5.230 |
Number of long holdings: 19
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Divi's Labs | INE361B01024 | 9.57 | 6,109.50 | +1.61% | |
RPG Life Sciences Limited | INE105J01010 | 9.28 | 2,126.70 | -5.24% | |
Aster DM Healthcare | INE914M01019 | 9.22 | 512.10 | +1.36% | |
Ipca Laboratories | INE571A01038 | 7.42 | 1,400.00 | -1.34% | |
Torrent Pharma | INE685A01028 | 7.31 | 3,328.10 | +2.75% | |
Alivus Life Sciences | INE03Q201024 | 7.20 | 1,050.50 | +1.37% | |
Zydus Lifesciences | INE010B01027 | 7.02 | 884.95 | +2.94% | |
Aurobindo Pharma | INE406A01037 | 6.82 | 1,256.10 | +2.95% | |
Reliance Industries | INE002A01018 | 6.69 | 1,361.00 | +4.66% | |
Zydus Wellness | INE768C01010 | 5.83 | 1,770.00 | +0.25% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
INF966L01689 | 248.93B | -11.46 | 21.86 | 19.42 | ||
INF966L01051 | 248.93B | -11.66 | 20.48 | 18.57 | ||
Quant Mid Cap Fund Growth | 83.56B | -7.88 | 17.03 | 16.14 | ||
INF966L01887 | 83.56B | -7.61 | 18.84 | 17.39 | ||
Quant Consumption Fund Growth | 67.12B | -4.91 | 16.05 | 18.05 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review